| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MCTACharming Medical Limited Class A Ordinary Shares | 445.55M | 29.36 | 414.62 | 3.43% | 19.27% | 24.35% | 0.03% | 23.57 |
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Sales/Revenue | 3.53M | 6.02M | 6.22M |
| Revenue Growth % | - | 0.7% | 0.03% |
| Cost of Goods Sold | 2.04M | 2.1M | 2.04M |
| COGS % of Revenue | 0.58% | 0.35% | 0.33% |
| Gross Profit | 1.49M | 3.91M | 4.18M |
| Gross Margin % | 0.42% | 0.65% | 0.67% |
| Gross Profit Growth % | - | 1.62% | 0.07% |
| Operating Expenses | 2.02M | 2.91M | 2.79M |
| OpEx % of Revenue | 0.57% | 0.48% | 0.45% |
| Selling, General & Admin | 1.66M | 2.35M | 2.32M |
| SG&A % of Revenue | 0.47% | 0.39% | 0.37% |
| Research & Development | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 353.39K | 555.41K | 474.14K |
| Operating Income | -521.34K | 1.01M | 1.39M |
| Operating Margin % | -0.15% | 0.17% | 0.22% |
| Operating Income Growth % | - | 2.94% | 0.38% |
| EBITDA | -310.26K | 1.4M | 1.65M |
| EBITDA Margin % | -0.09% | 0.23% | 0.27% |
| EBITDA Growth % | - | 5.51% | 0.18% |
| D&A (Non-Cash Add-back) | 211.08K | 391.7K | 263.45K |
| EBIT | -400.21K | 1.03M | 1.46M |
| Net Interest Income | -152.28K | -170.25K | -167.43K |
| Interest Income | 10.29K | 19.51K | 64.14K |
| Interest Expense | 20.26K | 26.05K | 20.87K |
| Other Income/Expense | 100.87K | -5.35K | 46.23K |
| Pretax Income | -420.47K | 1M | 1.44M |
| Pretax Margin % | -0.12% | 0.17% | 0.23% |
| Income Tax | -84.86K | 181.75K | 236.08K |
| Effective Tax Rate % | 0.73% | 0.78% | 0.84% |
| Net Income | -305.12K | 777.81K | 1.2M |
| Net Margin % | -0.09% | 0.13% | 0.19% |
| Net Income Growth % | - | 3.55% | 0.54% |
| Net Income (Continuing) | -335.61K | 821.74K | 1.2M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | -110.21K | -66.63K | 0 |
| EPS (Diluted) | -0.02 | 0.05 | 0.07 |
| EPS Growth % | - | 3.55% | 0.54% |
| EPS (Basic) | -0.02 | 0.05 | 0.07 |
| Diluted Shares Outstanding | 16.94M | 16.94M | 16.94M |
| Basic Shares Outstanding | 16.94M | 16.94M | 16.94M |
| Dividend Payout Ratio | - | - | - |
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Total Current Assets | 4.12M | 3.67M | 3.37M |
| Cash & Short-Term Investments | 1.93M | 2.1M | 2.76M |
| Cash Only | 1.93M | 2.1M | 816.77K |
| Short-Term Investments | 0 | 0 | 1.94M |
| Accounts Receivable | 2.12M | 1.54M | 579.09K |
| Days Sales Outstanding | 219.61 | 93.18 | 33.97 |
| Inventory | 66.33K | 28.15K | 26.8K |
| Days Inventory Outstanding | 11.89 | 4.89 | 4.79 |
| Other Current Assets | 0 | 0 | 0 |
| Total Non-Current Assets | 2.26M | 1.21M | 1.99M |
| Property, Plant & Equipment | 1.8M | 921.86K | 1.21M |
| Fixed Asset Turnover | 1.96x | 6.53x | 5.14x |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 |
| Other Non-Current Assets | 193.75K | 81.44K | 700.64K |
| Total Assets | 6.38M | 4.88M | 5.36M |
| Asset Turnover | 0.55x | 1.23x | 1.16x |
| Asset Growth % | - | -0.24% | 0.1% |
| Total Current Liabilities | 7.17M | 5.88M | 4.95M |
| Accounts Payable | 1.57K | 0 | 3.48K |
| Days Payables Outstanding | 0.28 | - | 0.62 |
| Short-Term Debt | 589.66K | 442.61K | 314.23K |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K |
| Other Current Liabilities | 0 | 0 | 0 |
| Current Ratio | 0.57x | 0.62x | 0.68x |
| Quick Ratio | 0.57x | 0.62x | 0.68x |
| Cash Conversion Cycle | 231.21 | - | 38.14 |
| Total Non-Current Liabilities | 484.26K | 148.25K | 358.03K |
| Long-Term Debt | 0 | 0 | 0 |
| Capital Lease Obligations | 484.26K | 148.25K | 358.03K |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 |
| Total Liabilities | 7.65M | 6.03M | 5.31M |
| Total Debt | 1.81M | 961.38K | 1.16M |
| Net Debt | -119.68K | -1.14M | 343.87K |
| Debt / Equity | - | - | 23.57x |
| Debt / EBITDA | - | 0.69x | 0.70x |
| Net Debt / EBITDA | - | -0.82x | 0.21x |
| Interest Coverage | -25.73x | 38.73x | 66.54x |
| Total Equity | -1.27M | -1.15M | 49.24K |
| Equity Growth % | - | 0.1% | 1.04% |
| Book Value per Share | -0.07 | -0.07 | 0.00 |
| Total Shareholders' Equity | -1.16M | -1.08M | 49.24K |
| Common Stock | 1.53K | 1.53K | 1.53K |
| Retained Earnings | -1.16M | -1.08M | 119.44K |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 3.92K | 205 | -3.57K |
| Minority Interest | -110.21K | -66.63K | 0 |
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Cash from Operations | 2.43M | 295.43K | 425.89K |
| Operating CF Margin % | 0.69% | 0.05% | 0.07% |
| Operating CF Growth % | - | -0.88% | 0.44% |
| Net Income | -335.61K | 821.74K | 1.2M |
| Depreciation & Amortization | 211.08K | 391.7K | 263.45K |
| Stock-Based Compensation | 0 | 0 | 0 |
| Deferred Taxes | 0 | 62.48K | 134.87K |
| Other Non-Cash Items | 60.9K | -37.45K | -10.89K |
| Working Capital Changes | 2.5M | -943.05K | -1.16M |
| Change in Receivables | -154.02K | -164.98K | -44.29K |
| Change in Inventory | -55.87K | 38.18K | 1.35K |
| Change in Payables | 180.4K | 210.28K | -204.69K |
| Cash from Investing | -606.19K | -210.6K | -2.23M |
| Capital Expenditures | -606.19K | -210.6K | -287.53K |
| CapEx % of Revenue | 0.17% | 0.04% | 0.05% |
| Acquisitions | - | - | - |
| Investments | - | - | - |
| Other Investing | 0 | 0 | 0 |
| Cash from Financing | -1.43M | 100.14K | 521.3K |
| Debt Issued (Net) | - | - | - |
| Equity Issued (Net) | - | - | - |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | - | - | - |
| Other Financing | -1.25M | 216K | 472.37K |
| Net Change in Cash | - | - | - |
| Free Cash Flow | 1.83M | 84.83K | 138.36K |
| FCF Margin % | 0.52% | 0.01% | 0.02% |
| FCF Growth % | - | -0.95% | 0.63% |
| FCF per Share | 0.11 | 0.01 | 0.01 |
| FCF Conversion (FCF/Net Income) | -7.98x | 0.38x | 0.36x |
| Interest Paid | 20.26K | 26.05K | 20.87K |
| Taxes Paid | 0 | 0 | 0 |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Return on Equity (ROE) | - | - | 2435.04% |
| Return on Invested Capital (ROIC) | - | - | 264.99% |
| Gross Margin | 42.31% | 65.07% | 67.19% |
| Net Margin | -8.64% | 12.93% | 19.27% |
| Debt / Equity | - | - | 23.57x |
| Interest Coverage | -25.73x | 38.73x | 66.54x |
| FCF Conversion | -7.98x | 0.38x | 0.36x |
| Revenue Growth | - | 70.37% | 3.43% |
Charming Medical Limited Class A Ordinary Shares (MCTA) has a price-to-earnings (P/E) ratio of 414.6x. This suggests investors expect higher future growth.
Charming Medical Limited Class A Ordinary Shares (MCTA) reported $6.2M in revenue for fiscal year 2024. This represents a 76% increase from $3.5M in 2022.
Charming Medical Limited Class A Ordinary Shares (MCTA) grew revenue by 3.4% over the past year. Growth has been modest.
Yes, Charming Medical Limited Class A Ordinary Shares (MCTA) is profitable, generating $1.2M in net income for fiscal year 2024 (19.3% net margin).
Charming Medical Limited Class A Ordinary Shares (MCTA) has a return on equity (ROE) of 2435.0%. This is excellent, indicating efficient use of shareholder capital.
Charming Medical Limited Class A Ordinary Shares (MCTA) generated $0.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.